Comparison of the anti-diabetic effects of resveratrol, gliclazide and losartan in streptozotocin-induced experimental diabetes

Basit Öğe Kaydı
dc.contributor.authorYazgan, Umit Can
dc.contributor.authorTasdemir, Ezel
dc.contributor.authorBilgin, Hakki Murat
dc.contributor.authorObay, Basra Deniz
dc.contributor.authorSermet, Abdurrahman
dc.contributor.authorElbey, Bilal
dc.date.accessioned2024-04-24T17:20:32Z
dc.date.available2024-04-24T17:20:32Z
dc.date.issued2015
dc.departmentDicle Üniversitesien_US
dc.description.abstractAim: The aim of this study was to compare the effect of the resveratrol with gliclazide and losartan in streptozotocin induced diabetic rats. Materials and methods: Adult male Wistar albino rats were divided into five groups of seven rats each. Diabetes was induced with a single intraperitoneal (i.p.) injection of streptozotocin (55mg/kg). Rats with blood glucose levels above 250mg/dl after 48h of streptozotocin injection were included in the diabetic group. Gliclazide and resveratrol were administered for 3 weeks at 5mg/kg per day and losartan was administered for 3 weeks at 30mg/kg per day in an oral aqueous suspension. At the end of the third week all rats were euthanized and fasting blood glucose, HbA1c and the metabolic activity of the hepatic enzymes hexokinase and glucose-6 phosphate dehydrogenase were measured in tail blood and liver specimens. All parameters were quantified using an ELISA plate reader. Results: Resveratrol and gliclazide significantly reduced both blood glucose levels and HbA1c levels in diabetic rats (p<0.001). However, losartan did not exhibit the same effects (p<0.05). The enzymatic activity of the liver enzymes hexokinase, glucose-6 phosphate dehydrogenase, fructose 1,6-biphosphatase, pyruvate kinase and glucose-6 phosphatase were enhanced by resveratrol and gliclazide, while losartan treatment was not associated with significant changes in liver carbohydrate metabolism. Conclusion: Resveratrol was not effective in improving liver carbohydrate metabolism relative to gliclazide, a drug widely used to treat diabetes. Dose-response profile of resveratrol remains indeterminate and additional studies may be necessary to determine effective dosing in diabetes.en_US
dc.identifier.doi10.3109/13813455.2015.1062898
dc.identifier.endpage161en_US
dc.identifier.issn1381-3455
dc.identifier.issn1744-4160
dc.identifier.issue4en_US
dc.identifier.pmid26161595
dc.identifier.scopus2-s2.0-84945132850
dc.identifier.scopusqualityQ1
dc.identifier.startpage157en_US
dc.identifier.urihttps://doi.org/10.3109/13813455.2015.1062898
dc.identifier.urihttps://hdl.handle.net/11468/19113
dc.identifier.volume121en_US
dc.identifier.wosWOS:000365606800005
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofArchives of Physiology and Biochemistry
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDiabetesen_US
dc.subjectGliclazideen_US
dc.subjectResveratrolen_US
dc.subjectStreptozotocinen_US
dc.titleComparison of the anti-diabetic effects of resveratrol, gliclazide and losartan in streptozotocin-induced experimental diabetesen_US
dc.titleComparison of the anti-diabetic effects of resveratrol, gliclazide and losartan in streptozotocin-induced experimental diabetes
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu